News
RMD
204.83
+2.53%
5.05
Eli Lilly’s GLP-1 impact on ResMed is overblown: Barron’s
Barron's says ResMed's stock sold off in reaction to positive data for Eli Lilly's GLP-1 therapy in obstructive sleep apnea. The publication says the MedTech company is attractive despite the selloff. ResMed (RMD) markets masks and CPAP machines for OSA.
Seeking Alpha · 2d ago
Resmed Poised for Growth: Strong U.S. Device Sales and SaaS Segment to Drive Performance Despite Industry Challenges
TipRanks · 3d ago
Here's Why ResMed (RMD) is a Strong Growth Stock
NASDAQ · 4d ago
Looking Into ResMed's Recent Short Interest
ResMed's short percent of float has fallen 16.56% since its last report. The company has 8.24 million shares sold short, which is 6.4% of all regular shares available for trading. Short interest is the number of shares that have been sold short but have not yet been covered.
Benzinga · 6d ago
Stock Market News From Amazon, Nike, McCormick, and More
Author Nicola Twilley talks about her new book, "Frostbite: How Refrigeration Changed Our Food, Our Planet" The Motley Fool Money radio show includes a look at the first 2024 presidential debate. A new company crossed the $2 trillion mark this week. Jason Moser and Bill Mann talk with Dylan Lewis about Amazon.
The Motley Fool · 07/08 15:56
Should You Hold STERIS (STE) Stock Now? Here's What to Consider
NASDAQ · 07/08 11:29
Weekly Report: what happened at RMD last week (0701-0705)?
Weekly Report · 07/08 09:17
Charles River (CRL) Could be an Apt Pick Right Now: Here's Why
NASDAQ · 07/05 13:23
Here's Why Staying Invested in Neogen (NEOG) Could be Beneficial
NASDAQ · 07/05 13:12
ResMed: Potentially Undervalued Amid Increasing Sleep Apnea Awareness
ResMed is a global leader in digital health and connected medical devices. The company holds 55-62% of the market share in obstructive sleep apnea treatment. ResMed is potentially undervalued and has untapped growth potential in OSA treatment. The stock is currently trading at a 31.65% discount from its 5-year average price.
Seeking Alpha · 07/03 22:19
Omnicell (OMCL) Banks on Product Launches, Global Growth
NASDAQ · 07/03 15:39
ResMed to Report Fourth Quarter Fiscal 2024 Earnings on August 1, 2024
ResMed plans to release financial and operational results for the fourth quarter of fiscal year 2024 on Thursday, August 1, 2024. ResMed management will host a webcast to discuss the results. The company will release the results after the New York Stock Exchange closes on Thursday.
Barchart · 07/03 15:05
ResMed: Asymmetrical Value Opportunity With High Prospect Of Re-Rating
ResMed's competitive advantages in the sleep domain are durable, and its underlying business remains strong. ResMed is in the business of diagnosing, treating, and managing respiratory disorders. The company is attractively valued based on future growth opportunities, resilient returns on capital, and potential for multiple expansions.
Seeking Alpha · 07/03 12:44
Zacks.com featured highlights include ResMed, Badger Meter, Leidos and Ingersoll Rand
NASDAQ · 07/03 12:40
Thermo Fisher (TMO) Brings Biobased, Sustainable Films for BPCs
NASDAQ · 07/03 12:16
4 Top Earnings Growth Stocks to Buy: RMD, BMI, LDOS, IR
NASDAQ · 07/02 18:45
How Great Is It to Have Customers That Absolutely Love You and Plan to Never Leave You?
Motley Fool analyst Bill Barker and host Dylan Lewis talk about weight loss drugs and sleep apnea. Shares of Med Tech company ResMed down 10% after studies show new drugs may help reduce the severity of sleep Apnea. They also look at the value of lifetime customer relationships. The Motley Fool Money podcast also looks at other stock market news.
The Motley Fool · 07/02 17:47
An Intrinsic Calculation For ResMed Inc. (NYSE:RMD) Suggests It's 33% Undervalued
ResMed Inc. (NYSE:RMD) is estimated to be 33% undervalued based on a discounted cash flow model. The company is valued at a 33% discount to its fair value. We use a 2-stage model to estimate the future cash flows of the company and discount them to today's value. The projected fair value for ResMed is US$280 based on 2 Stage Free Cash Flow to Equity. RMD's share price is 21% less than the company's actual value.
Simply Wall St · 07/02 10:42
Tandem Diabetes (TNDM) Posts Positive Data for Tandem Mobi
NASDAQ · 07/01 20:24
Walgreens Boots (WBA) Q3 Earnings Miss, Gross Margin Down
NASDAQ · 07/01 11:59
More
Webull provides a variety of real-time RMD stock news. You can receive the latest news about Resmed through multiple platforms. This information may help you make smarter investment decisions.
About RMD
ResMed Inc. is a holding company. The Company, through its subsidiaries, is engaged in the development, manufacturing, distribution and marketing of medical devices and cloud-based software applications that diagnose, treat and manage respiratory disorders, including sleep disordered breathing (SDB), chronic obstructive pulmonary disease, neuromuscular disease and other chronic diseases. The Company’s segments include Sleep and Respiratory Care and Software as a Service. SDB includes obstructive sleep apnea and other respiratory disorders that occur during sleep. Its cloud-based digital software health applications, along with its devices, are designed to provide connected care to improve patient outcomes. Its portfolio of products includes devices, diagnostic products, mask systems, headgear and other accessories, dental devices, and cloud-based software and informatics solutions. Its comprehensive out-of-hospital software platforms support the professionals and caregivers.